Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.4.17 (
adenosine deaminase
)
5,206
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
1. Enzymes interconnecting the adenylate pool were present in high concentration. 2. AMP and adenosine were easily deaminated by the corresponding enzymes whose high levels were detected. 3. Adenylate was hydrolyzed either by deamination to yield IMP which was further dephosphorylated to inosine or by dephosphorylation to adenosine followed by deamination to inosine. 4. Incubation of gill extract with [-14C]-AMP in the presence and absence of
ATP
but with
adenosine deaminase
inhibitors allowed demonstration that
ATP
controlled the balance between these pathways. 5. Some biochemical properties of 5'-nucleotidase. AMP deaminase and
adenosine deaminase
were defined. 6. Purine salvage enzymes were also estimated.
...
PMID:Aspects of purine metabolism in the gill epithelium of rainbow trout, Salmo gairdneri Richardson. 31 37
Deoxyadenosine was identified in the urine of a second child with almost undetectable levels of
adenosine deaminase
(
ADA
) in erythrocyte lysates. Deoxyadenosine excretion thus appears to be characteristic of ADA deficiency: the acid lability of deoxyadenosine (responsible for the frequent confusion of this abnormal urinary metabolite with adenine) may be used in screening for this defect by isotachophoresis. The deoxynucleotides dATP, dADP and dAMP found initially in the child's erythrocytes (in comparable amounts to
ATP
, ADP and AMP) disappeared after a successful marrow graft from an unrelated donor, as did the urinary deoxy metabolites. Erythrocyte
ADA
activity decreased after the marrow graft but was still greater than 10% of normal congruent to 10 weeks after the last red cell transfusion.
...
PMID:Purine metabolism in adenosine deaminase deficiency. 38 57
The effect of adenosine on the mitogenic response of peripheral blood lymphocytes (PBL) and on the nucleotide pools of erythrocytes from normal horses, horses heterozygous for the combined immunodeficiency (CID) trait (carriers), and foals with CID was studied. When PBL from normal, carrier, and CID horses were stimulated by phytohemagglutinin (PHA), concanavalin A, or pokeweed mitogen, [3H]thymidine uptake was inhibited by adenosine (0.1 microM) to 1.0 mM) in a dose-dependent manner. Adenosine (100 microM) mediated inhibition of [3H]thymidine uptake was prevented in both normal and carrier horse PBL by incubation with uridine. Uridine had no sparing effect on PBL from horses with CID. Differences were detected between human and horse PBL in response to adenosine and erythro-9(2-hydroxy-3-nonyl) adenine (EHNA), a competitive inhibitor of
adenosine deaminase
. In the first assay, mitogen-stimulated PBL from horses were more sensitive to adenosine. In the second assay, adenosine was added to PBL cultures at various times after PHA addition. Adenosine inhibited mitogenesis in horse PBL if added within the first 24 h. In human PBL cultures, adenosine inhibited mitogenesis only if added within the first 4 h. The third assay measured capacity of PHA-stimulated human and horse lymphocytes to escape inhibition by adenosine or EHNA. At the end of a 72-h culture period, horse PBL were still inhibited of mitogenesis in both human and horse PBL. With prolonged incubation (72 h), synergistic inhibition was detected only in horse PB. With high-pressure liquid chromatography, nucleotide levels in erythrocytes of normal, carrier, and CID horses were found to be similar. Incubation with adenosine produced a 1.5- to 2-fold increase in total adenine nucleotide pools in erythrocytes from all horses. However, these increases were accompanied by alterations in the relative amounts of the nucleotide components. This was seen as a significant decrease in the
ATP
:(AMP plus ADP plus
ATP
) ratio and energy charge in erythrocytes from normal horses. In contrast, the
ATP
:(AMP plus ADP plus
ATP
) ratio decreased only slightly in erythrocytes from CID horses, whereas no change in the energy charge was detected. The data from these studies indicate a difference in adenosine metabolism exists between human and horse lymphoyctes, and an abnormality may exist in purine metabolism or in an interconnecting pathway in horses with CID.
...
PMID:In vitro of adenosine on lymphocytes and erythrocytes from horses with combined immunodeficiency. 44 64
The vascular effects of several purine compounds were evaluated using isolated arteries from bovine heart and tongue. At almost all concentrations tested, adenosine, AMP, ADP,
ATP
, guanosine, GMP, GDP and inosine produced significant relaxation of the lingual artery. In general, these compounds were much less effective in the coronary artery. Dipyridamole and nitrobenzylthioinosine (NBMPR), compounds which block the cellular uptake of nucleosides, partially prevented the actions of these compounds in the lingual artery but not in the coronary artery. Erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA), a potent inhibitor of
adenosine deaminase
also altered the relaxant effect of adenosine. These results suggest that at least part of the action of purine compounds on the vascular smooth muscle of the lingual artery is a result of an intracellular effect.
...
PMID:Effect of purine compounds on the vascular responsiveness of bovine coronary and lingual arteries. 47 13
Adenine nucleotide breakdown to nucleosides and purine bases was measured in cultures of human lymphoblastoid cells following: 1) the inhibition of oxidative phosphorylation in the absence of glucose or 2) the addition of 2-deoxyglucose. A mutant cell line, deficient in adenosine kinase, in the presence of an
adenosine deaminase
inhibitor was used to measure utilization of the two pathways of AMP catabolism involving initial action of either purine 5'-nucleotidase or AMP deaminase. In such a system the appearance of adenosine induced by the oxidative phosphorylation inhibitor, rotenone, implies that approximately 70% of AMP breakdown occurs via dephosphorylation. By the same method, deamination accounts for 82% of AMP breakdown when 2-deoxyglucose is added. The occurrence of AMP dephosphorylation is not correlated with elevated concentrations of substrate or with decreased concentrations of the inhibitors of 5'-nucleotidase,
ATP
and ADP. Dephosphorylation occurs if, and only if, the adenylate energy charge decreases to about 0.6 in these experiments. In cultures deprived of glucose and oxygen, adenine nucleotide degradation via dephosphorylation results in recovery of normal energy charge values.
...
PMID:Adenine nucleotide degradation during energy depletion in human lymphoblasts. Adenosine accumulation and adenylate energy charge correlation. 47 72
Adenylate deaminase from rat skeletal muscle has been studied with the objective of understanding how the activity of the enzyme is regulated in vivo.
ATP
and GTP inhibit the enzyme at low concentrations in the presence of 150 mM KCl. The
ATP
inhibition is reversed as the
ATP
concentration is raised to physiological levels. The GTP inhibition is reversed as the GTP concentration is raised to unphysiologically high levels. In the presence of physiological concentrations of
ATP
, the GTP inhibition is also greatly diminished, but inhibition by orthophosphate remains strong. The apparent affinities of the enzyme for GTP,
ATP
, and orthophosphate are reduced as the pH is decreased from 7.0 to 6.2. ADP also reduces the apparent affinities of the enzyme for the inhibitors. The regulatory effects of GTP,
ATP
, and ADP are produced primarily by their unchelated forms. Comparison of the kinetic behavior of the enzyme in vitro with metabolite concentrations in vivo indicates that the major variables that regulate the activity of
adenylate deaminase
of muscle in vivo are the concentrations of AMP, ADP, orthophosphate, and H+.
...
PMID:Adenylate deaminase from rat muscle. Regulation by purine nucleotides and orthophosphate in the presence of 150 mM KCl. 47 76
Inherited deficiency of the purine salvage enzyme
adenosine deaminase
(
ADA
) gives rise to a syndrome of severe combined immunodeficiency (SCID). We have studied a 2.5-yr-old immunologically normal child who had been found to lack
ADA
in his erythrocytes during New York State screening of normal newborns. His erythrocytes were not detectably less deficient in
ADA
than erythrocytes of
ADA
(-)-SCID patients. In contrast, his lymphocytes and cultured long-term lymphoid cells contained appreciably greater
ADA
activity than those from patients with
ADA
(-)-SCID. This residual
ADA
activity had a normal molecular weight and K(m) but was markedly unstable at 56 degrees C. His residual erythrocytes-
ADA
activity also appeared to have diminished stability in vivo.
ADA
activity in lymphoid line cells of a previously reported erythrocyte-
ADA
-deficient!Kung tribesman was found to contain 50% of normal activity and to exhibit diminished stability at 56 degrees C.
ATP
content of erythrocytes from both partially
ADA
-deficient individuals was detectably greater than normal (12.3 and 6.1 vs. normal of 2.6 nmol/ml packed erythrocytes). However, the dATP content was insignificant compared to that found in erythrocytes of
ADA
(-)-SCID patients (400-1,000 nmol/ml packed erythrocytes). The New York patient, in contrast to normals, excreted detectable amounts of deoxyadenosine, but this was <2% of deoxyadenosine excreted by
ADA
(-)-SCID patients. Thus, the residual enzyme in cells other than erythrocytes appears to be sufficient to almost totally prevent accumulation of toxic metabolites.
...
PMID:Erythrocyte adenosine deaminase deficiency without immunodeficiency. Evidence for an unstable mutant enzyme. 47 73
A case of red cell
adenosine deaminase
(
ADA
) overproduction associated with hereditary hemolytic anemia is reported here. This appears to be the second report. Proband is a 38-year-old Japanese male who had hemoglobin, 15.8 g/100 ml; reticulocyte count, 4.5%; serum indirect bilirubin, 4.9 mg/100 ml; 51Cr-labeled red cell half-life, 12 days; red cells showed moderate stomatocytosis. His red cell
ADA
activity showed 40-fold increase while that of the mother showed 4-fold increase. The mother was hematologically normal. The father had a normal enzyme activity. The proband and the mother showed slightly high serum uric acid levels. The proband's red cell showed:
ATP
, 628 nmoles/ml (normal, 1,010--1,550); adenine nucleotide pool, 46% of the normal mean; 2,3-diphosphoglycerate content, 3,782 nmoles/ml (normal 4,170--5,300); increased oxygen affinity of hemoglobin, P50 of intact erythrocytes being 21.8 mmHg (normal, 24.1--26.1). Red cell glycolytic intermediates in the proband were low in general, and the rate of lactate production was low. Kinetic studies using crude hemolysate revealed a normal Km for adenosine, normal electrophoretic mobility but slightly abnormal pH curve and slightly low utilization of 2-deoxyadenosine. The
ADA
activity of lymphocytes was nearly normal.
...
PMID:A case of red-cell adenosine deaminase overproduction associated with hereditary hemolytic anemia found in Japan. 73 30
To elucidate the mode of action of hexobendine, its effects on some enzyme activities, the uptake of adenosine by rat erythrocytes and changes in the concentration of various myocardial substrates following induced hypoxia in rat were studied. Hexobendine had no effect on the in vitro activities of the adenosine degrading enzyme,
adenosine deaminase
and of the A-PRTase, HG-PRTase which are associated with the salvage pathways of purine biosyntheses. The uptake of adenosine by rat erythrocytes in vitro was inhibited considerably by hexobendine. Hypoxic states results in a significant decrease in creatine phosphate,
ATP
, glycogen and glucose contents, and increase in ADP, AMP, adenosine and lactate contents in rat myocardials. These alterations in cardiac metabolism induced by hypoxia were significantly improved by hexobendine given orally in doses of 10 approximately 100 mg/kg. Thus, hexobendine was shown to maintain the normal aerobic energy metabolism of the heart under states of hypoxia. In such states adenosine may be released from tissues and this increase in the available concentration of adenosine in plasma through inhibition of uptake by erythrocytes may be involved in the coronary vasodilating action of hexobendine.
...
PMID:[Effects of hexobendine on adenosine metabolism and myocardial energy metabolism (author's transl)]. 74 50
Severe Combined Immunodeficiency (SCID) is a fatal disorder of infancy in which patients exhibit profound defects of both cellular and humoral immune function. Approximately 50% of patients with the autosomal recessive form of SCID have a genetically determined deficiency of the purine salvage enzyme
adenosine deaminase
(
ADA
). Prenatal diagnosis of SCID-ADA deficiency has been successful and detection of heterozygous carriers has been shown to be feasible. A mutation at the structural locus for
ADA
has been found in several cases but clinical heterogeneity indicates that genetic heterogeneity at the molecular level is to be expected. In vitro model studies and clinical course suggest that the pathophysiology may involve primarily an inhibition of T-cell maturation with lesser effects on B-cell maturation as well as "self-destruction" of differentiated cells following antigen stimulation. The culprit may be adenosine itself or one of its metabolites such as
ATP
or cAMP, which are elevated in these patients. Bone marrow transplantation remains the recommended mode of therapy but red cell transfusion may offer an alternative when bone marrow transplantation is not feasible. The finding that deficiency of the next enzyme in the purine salvage pathway, nucleoside phosphorylase, is also associated with an immune deficiency disorder suggests that integrity of the purine salvage pathway may be crucial for normal differentiation and function of immunocompetent cells in man.
...
PMID:Adenosine deaminase deficiency and immunodeficiencies. 87 49
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>